Concepedia

Publication | Open Access

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

DOIFull Paper Access

69

Citations

22

References

2015

Year

Steven G. DuBois, Susan Groshen, Julie R. Park, Daphne A. Haas‐Kogan, Xiao-Dong Yang, Ethan G. Geier, Eugene Chen, Kathy Giacomini, Brian Weiss, Susan L. Cohn,
Clinical Cancer Research

Abstract

Vorinostat at 180 mg/m(2)/dose is tolerable with 18 mCi/kg MIBG. A phase II trial comparing this regimen to single-agent MIBG is ongoing.

References

YearCitations

Page 1